U.S. Mortgage Finance Stock News

If you’re eyeing Alphabet’s stock and wondering whether it’s still a buy after this year’s headlines, you’re not alone. The past few months have taken investors on a bit of a roller coaster, with Alphabet’s share price moving up about 5% in the past 30 days and jumping more than 20% over the last year. Quick dips, such as the recent 1% decline after news of a $30 million YouTube privacy settlement, haven’t changed the overall upward trend. These brief setbacks usually reflect short-term risk...

If you are considering what to do with Hewlett Packard Enterprise (HPE) stock right now, you are certainly not alone. The past few months have been anything but boring for HPE investors, with the share price riding out some dramatic news stories and showing signs that fresh growth might be on the horizon. In the past three months alone, HPE stock has surged nearly 20%, which is notable even against the broader technology sector. There has been real momentum. While the one-day and week-long...

Molina Healthcare (MOH) has caught some investor attention after a muted patch, with its stock slipping almost 50% over the past year. There is no single event behind this movement, but the drop is hard to ignore if you have been following the healthcare sector. Such sizable declines are uncommon without changes in company expectations or industry sentiment. As a result, it is worth a closer look at what is really moving the shares and whether the story has shifted beneath the surface. Over...

Thinking about what to do with Zscaler stock right now? You are definitely not alone. Whether you have been riding the cybersecurity wave for years or are just now eyeing the opportunity, it is no wonder Zscaler pops up on your radar given its momentum. The company’s shares are up an impressive 50.7% so far this year, and a stunning 95.6% over the past five years, even with some bumps along the way. Yet, in the last month, the stock has pulled back around 5%. For anyone watching, this kind of...

NasdaqCM:WALD 1 Year Share Price vs Fair Value Explore Waldencast's Fair Values from the Community and select yours The...

If you have been tracking Intuitive Surgical, you might be wondering if this is a smart time to buy in, hold steady, or wait for a better price. With its robotic-assisted surgery technology, the company has long commanded investor attention, but recent price swings may have left some feeling uncertain. In the last three months alone, Intuitive Surgical’s stock has given up about 11%. If you zoom out to three or five years, the returns have been stellar, up over 100% in both periods. Clearly,...

If you have been following ConocoPhillips (COP), you probably noticed the latest action after the company released its second-quarter earnings. While sales and revenue climbed over last year, net income and earnings per share dipped, leaving some investors reassessing what this mixed performance means for their portfolios. At the same time, management reaffirmed production guidance for the full year, which has nudged confidence that operational targets are on steady ground. In addition,...

Thinking about whether to buy, hold, or sell AppLovin stock right now? You're not alone. With AppLovin’s price jumping nearly 18% over the past month and a massive 363% surge in the past year, plenty of investors are trying to figure out what is driving this momentum. While past returns never guarantee future results, such strong performance can change how people perceive the company’s risk and growth potential. AppLovin has benefited from surging demand in the mobile advertising and app...

Sirius XM Holdings (SIRI) has been on the radar lately after its stock price dipped nearly 3% in a single day, sparking fresh debate among shareholders about what is driving the latest moves. While there is not one headline-grabbing event behind this shift, the recent drop is hard to ignore for anyone following the satellite radio space. Whether you are holding shares or thinking about getting in, this price action is a good reminder to revisit what is happening under the hood at Sirius...

Rhythm Pharmaceuticals (RYTM) just received a significant decision from the FDA, as their supplemental New Drug Application for setmelanotide was not only accepted for filing but also granted Priority Review status. This indicates that the agency sees potential for the medication to address an urgent, unmet need for people dealing with acquired hypothalamic obesity. Investors familiar with Rhythm know setmelanotide already has approvals for rare genetic obesity disorders. This proposed...

DENTSPLY SIRONA Inc. announced its second quarter 2025 results in August, revealing sales of US$936 million and a net loss of US$45 million, with management reaffirming its full-year sales guidance of US$3.60 billion to US$3.70 billion amid continued industry headwinds. An interesting aspect is the board’s decision to maintain its dividend at US$0.16 per share, contrasting with ongoing revenue pressure and signaling a commitment to shareholder returns despite financial challenges. We’ll...

Thinking about investing in Vulcan Materials, or maybe deciding whether to hold on to your shares? You are in good company. Vulcan Materials has caught the attention of market watchers, especially after its stock price shrugged off some short-term dips and delivered an impressive 16.4% return over the past year. That is a performance hard to ignore, especially when you look at its nearly 143% total return over five years. Recent months have shown a blend of resilience and optimism, with the...

If you have your eye on Live Nation Entertainment stock, you are not alone. With concerts and live experiences roaring back, investors have seen the company’s share price climb an impressive 25% so far this year and over 67% over the past twelve months. That kind of run naturally raises the question: does LYV have more room to run, or is the market already pricing in all that potential? Digging a bit deeper, LYV’s journey has been anything but boring. In just the past three months, the stock...

NasdaqGS:JD 1 Year Share Price vs Fair Value Explore JD.com's Fair Values from the Community and select yours JD.com...

Thinking about what to do with Pony AI stock? You are not alone. As one of the more intriguing names in the autonomous vehicle sector, Pony AI has experienced its fair share of twists and turns recently. For traders and long-term investors alike, the past few months have brought some big price swings that demand a closer look. Let us start with the numbers. After a dip of nearly 28% over the past 90 days, Pony AI has rebounded with a 15.6% climb over the last month. That recent rally, coupled...

Thinking about whether to hold, buy, or sell Oracle? You are in good company. Oracle’s stock has experienced considerable volatility, with short-term dips but significant growth over the past year. In just the last 90 days, shares are up almost 50%, and that one-year return is nearly 70%. Clearly, something notable is happening behind the scenes. What is driving these swings? For one, Oracle continues to secure major deals and draw investment headlines. Over the past month, news broke that...

Thinking about what to do next with Johnson Controls International stock? You are not alone. Investors have been watching JCI’s distinct price action over the past year and weighing up the company’s future, especially as expectations across the industrial sector keep shifting. After a rollercoaster 2023, the past twelve months have brought a substantial total return of about 53% for Johnson Controls’ shareholders. That impressive run comes in addition to a hefty 104% return over three years,...

Key Insights TROOPS' significant insider ownership suggests inherent interests in company's expansion A total of 3...

If you are trying to make sense of Insulet’s recent run, you are not alone. Whether you already hold shares or are weighing a new buy, it is tough to look away from a stock that has powered up nearly 30% year-to-date and delivered a whopping 79% total return over the past year. The buzz makes sense, with Insulet’s sales up by more than 14% and annual net income growth topping 23%. All of this comes with the shares closing recently at $333, just a modest 5.7% below the average analyst price...

On August 12, 2025, Insmed Incorporated announced that the U.S. FDA approved BRINSUPRI (brensocatib), the first and only FDA-approved oral therapy for non-cystic fibrosis bronchiectasis in adults and children 12 years and older, with Maxor Specialty Pharmacy later selected as a limited distribution provider. This approval not only introduces a first-in-class treatment for an underserved patient population but also positions Insmed to potentially establish a new standard of care for...

If you have been following Cigna Group (CI) lately, you’ve probably noticed the stock’s share price drifting higher. The increase has been subtle, but just enough to catch the eye. There hasn’t been a single major announcement sparking this move; however, with a share price now sitting above $300 and a year-to-date gain over 10%, many investors are wondering whether the recent momentum is revealing something about sentiment or simply reflects the normal ebb and flow of a maturing company...

W. R. Berkley (WRB) just unveiled Berkley Edge, a brand-new operation dedicated to serving small and mid-sized businesses with professional liability and casualty insurance, especially in cases that are tough to underwrite. This move, along with the appointment of industry veteran Jamie Secor to lead the venture, is a clear statement about where the company sees opportunity: in specialty insurance, targeting risks that many competitors pass by. For investors, this expansion is worth a closer...

If you are sitting on the fence about what to do with BWX Technologies stock right now, you are definitely not alone. With its impressive run over the last year, climbing more than 63%, BWXT has landed squarely on the radar for many investors searching for growth stories and stable plays alike. The stock’s gains are even more eye-catching when you zoom out, doubling over the last three and five years, and surging more than 51% in just the past three months. These outsized returns tell a story...

It is not every day that Novo Nordisk (NYSE:NVO) catches eyes for all the wrong reasons, but this week’s slide has certainly prompted investors to pause. The stock dropped by roughly 0.9% in the past day and now sits a staggering 58% below its level a year ago. While there is no single dramatic event driving these shifts, the persistent decline has many wondering whether this signals deeper issues or simply reflects changing market sentiment around the pharmaceutical sector. Looking at a...